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848have all been tested and used to determine the opti-
mal angiographic deployment projection angle (1–3).
Thesemodalities, however, remain limited by the need
for iodinated contrast, which carries with it inherent
risks of subsequent renal dysfunction in the elderly
and high-risk TAVR patients. Recently, an integrated
3D Echo-X-Ray navigation system (EchoNavigator,
Philips Healthcare, Eindhoven, the Netherlands) was
employed whereby 3D transesophageal echocardiog-
raphy (TEE) imaging is registered automatically in real
time with live 2-dimensional ﬂuoroscopy images ac-
quired from the x-ray imaging system. Although use of
this integrated navigation system to determine an
optimal x-ray angiographic deployment projection
necessitates the use of TEE during TAVR, it offers the
potential to mitigate some of the contrast agent risk
associated with the alternative imaging modalities.
Figure 1 demonstrates a case example using x-ray/3D
TEE coregistration to accurately predict the optimal
x-ray angiographic deployment projection for TAVR.
Further investigation of the methods described in
this case example should be validated in a larger
series of patients.Michael S. Kim, MD*
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Extracellular Volume CalculationWe read with much interest the recent publication by
White et al. (1), assessing the accuracy of the contrast
bolus T1 mapping cardiac magnetic resonance
technique for measuring myocardial extracellular
volume fraction (ECV). The study provides the ﬁrst
validation of the bolus technique against collagen
volume fraction from myocardial biopsy. The bolus
technique was also compared with the gold standard
infusion technique in 5 representative conditions.
The 2 techniques provide equivalent results, except
for pathological states with an ECV >0.4, where
the bolus approach consistently and increasingly
overestimates the ECV value.
To date, T1 mapping has been used mainly for
differentiation between healthy and disease states in
clinical settings associated with an increased ECV.
The technique should provide even more clinical
beneﬁt through its ability to differentiate between
different degrees of pathological states associated
with scar or edema in such settings as post-infarction
remodeling, myocarditis, and transplant rejection
follow-up. In this regard, the lower precision of the
bolus technique in the ECV range of myocardial scar
or edema is a matter of concern.
As suggested by the authors, a possible reason for
such ECV overestimation is that renal clearance might
be faster than the exchange rate between the intra-
vascular and interstitial compartments, leading to
lower DR1 in blood compared with DR1 of myocar-
dium with time. This is in line with previous obser-
vations in subjects with normal or modestly increased
ECV, showing small but signiﬁcant changes in ECV
with time using the bolus approach (2,3). This should
cause a slight overestimation in the high ECV range
with the bolus approach, as a limitation of the 2-
compartment model, but independent of noticeable
differences in blood T1 related to the underlying
clinical state.
The data in the present study show some intriguing
differences in blood T1 between groups. Post-contrast
blood T1 is higher for bolus than for infusion in all
subjects except for the healthy and the HCM-remote
groups. This includes therefore all cases of high
ECV (i.e., the Amyloid, HCM LGE Zone, and Infarct
Zone groups in Table 1 in White et al. (1)). As such, the
relative difference in blood T1 between bolus and
infusion (with pre-contrast T1 as the reference) is up
to 4.3 times higher in the high ECV subjects
compared with the healthy or HCM-remote group.
The lower DR1 for blood with the bolus approach in
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to the higher calculated ECV with this method. This is
most striking for the HCM-LGE subgroup compared
with the HCM-remote group and raises the question
of whether the observed differences in blood T1
between groups do not reﬂect different equilibrium
states between blood and myocardium according to
the study groups.
Multiple factors may contribute to the higher blood
T1 with the bolus approach in subjects with disease.
Heart rate or ﬂow-dependent variations in blood
inversion could lower the accuracy of T1 measure-
ment (4). Altered blood clearance through renal
impairment and synovial third-space penetration of
contrast may also act as confounders. More complex
examinations in disease may produce lower image
quality, altering intrastudy ECV reproducibility as a
factor of time (5).
We are aware of the complex nature of myocardial
T1 measure, of multiple factors interfering with ECV
calculation and we much appreciate the transparency
and completeness of data provided. We would like to
know the authors’ interpretation of the blood T1 data.
We believe this is an issue of practical interest in a
ﬁeld expected to provide a key biomarker in cardiac
disease in the future.Andrei Codreanu, MD*
Pauline Ferry, MBS
Marine Beaumont, PhD
Pierre-Yves Marie, MD, PhD
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90–7.REPLY: Effects of Blood T1 on
Extracellular Volume CalculationWe thank Dr. Codreanu and colleagues for their inter-
est in our paper (1). This study explored whether extra-
cellular volume fraction (ECV) measurement using a
bolus-only approach was equivalent to the (cumber-
some and time-consuming) primed infusion protocol.
If so, it takes this promising novel biomarker a
step closer to routine clinical applicability (2). We
conﬁrmed no apparent detriment to the relationship
with collagen volume fraction in low ECV states,
but in high ECV states, the bolus-only approach
measured the ECV higher.
How to scrutinize this discrepancy? First, although
reasonable, it is an assumption that the primed infu-
sion technique is the truth standard. Second, given
sufﬁcient time, the infusion approach needs no
priming bolus; the blood gadolinium (Gd) concentra-
tions will gradually rise to an infusion rate:renal
clearance equilibrium. We, however, use a primed
infusion with ﬁxed bolus (per kilogram), ﬁxed delay,
and ﬁxed infusion rate (per kilogram). The choice of
these affects whether the 15-min T1 is higher than,
equal to, or lower than the equilibrium T1. Here in
high ECV states, the 15-min pseudoequilibrium T1 was
higher than the infusion equilibrium (i.e., Gd blood
concentrations climb to equilibrium). Possible expla-
nations include factors that affect peak blood con-
centration, any of the Gd decay rate constants (blood
redistribution, tissue distribution and renal function),
and ﬁnal resting equilibrium (renal function and body
composition). Our suspicion is that high ECV patients
have worse renal function and are generally leaner
(thus proportionally overdosed with Gd).
Does this matter? For an infusion approach, a
bolus þ delay þ infusion rate normogram based on
pharmacodynamic/kinetic modeling, lean body mass,
and renal function could be constructed, aiming for
an identical equilibrium Gd concentration. Provided
the T1 mapping sequence sensitivity is stable over
the clinical range of T1 measured and provided Gd
concentrations are not so high that relaxation of
intracellular water ceases to be within the fast
exchange limit, individualization is probably not
necessary. Other possible approaches include serial
time point measurements to create a curve (the
Jerosch-Herold method) (3) and a bolus-only approach
with serial measurement and ECV calculation at a
ﬁxed blood T1 or Gd concentration (rather ﬁxed time
post bolus).
It is clear we do not understand all the issues.
Currently, however, our interpretation is that,
excepting amyloidosis research (tracking change over
